| 1802- | NarG, | ATV, | Bioenhancing effects of naringin on atorvastatin |
| - | in-vivo, | Nor, | NA |
| 1801- | NarG, | A Narrative Review on Naringin and Naringenin as a Possible Bioenhancer in Various Drug-Delivery Formulations |
| - | Review, | Var, | NA |
| 1800- | NarG, | Naringenin |
| - | Human, | Nor, | NA |
| 1799- | NarG, | Naringenin as potent anticancer phytocompound in breast carcinoma: from mechanistic approach to nanoformulations based therapeutics |
| - | Review, | NA, | NA |
| 1268- | NCL, | carbop, | Inhibition of Wnt/β-catenin pathway by niclosamide: a therapeutic target for ovarian cancer |
| - | in-vitro, | Ovarian, | NA |
| 1269- | NCL, | Identification of Niclosamide as a New Small-Molecule Inhibitor of the STAT3 Signaling Pathway |
| - | in-vitro, | Pca, | DU145 |
| 1270- | NCL, | Rad, | Niclosamide enhances the antitumor effects of radiation by inhibiting the hypoxia-inducible factor-1α/vascular endothelial growth factor signaling pathway in human lung cancer cells |
| - | in-vivo, | Lung, | NA |
| 1271- | NCL, | Niclosamide inhibits ovarian carcinoma growth by interrupting cellular bioenergetics |
| - | vitro+vivo, | Ovarian, | SKOV3 |
| 1267- | NCL, | Niclosamide suppresses migration of hepatocellular carcinoma cells and downregulates matrix metalloproteinase-9 expression |
| - | in-vitro, | HCC, | NA |
| 5253- | NCL, | Niclosamide: Beyond an antihelminthic drug |
| - | Review, | Var, | NA |
| 5254- | NCL, | The magic bullet: Niclosamide |
| - | Review, | Var, | NA |
| - | Trial, | Nor, | NA |
| 6774- | Neem, | The Antimicrobial Potential of the Neem Tree Azadirachta indica |
| - | Review, | Nor, | NA |
| 6775- | Neem, | Nimb, | Therapeutics Role of Azadirachta indica (Neem) and Their Active Constituents in Diseases Prevention and Treatment |
| - | Review, | Nor, | NA |
| 6493- | Nimb, | Nimbolide, a Limonoid Triterpene, Inhibits Growth of Human Colorectal Cancer Xenografts by Suppressing the Proinflammatory Microenvironment |
| - | in-vivo, | CRC, | HCT116 | - | vitro+vivo, | CRC, | HT29 |
| 6494- | Nimb, | Microwave-Assisted Improved Extraction and Purification of Anticancer Nimbolide from Azadirachta indica (Neem) Leaves |
| - | Study, | Nor, | NA |
| 6491- | Nimb, | Nanodelivery and anticancer effect of a limonoid, nimbolide, in breast and pancreatic cancer cells |
| - | Review, | PC, | NA |
| 6492- | Nimb, | Review on Molecular and Chemopreventive Potential of Nimbolide in Cancer |
| - | Review, | NA, | NA |
| 6490- | Nimb, | Nimbolide, a neem limonoid inhibits cytoprotective autophagy to activate apoptosis via modulation of the PI3K/Akt/GSK-3β signalling pathway in oral cancer |
| - | in-vitro, | Oral, | SCC4 |
| 6489- | Nimb, | Nimbolide-Induced Oxidative Stress Abrogates STAT3 Signaling Cascade and Inhibits Tumor Growth in Transgenic Adenocarcinoma of Mouse Prostate Model |
| - | in-vivo, | Pca, | DU145 | - | in-vivo, | Pca, | LNCaP |
| 6488- | Nimb, | Harnessing the Anti-Cancer Natural Product Nimbolide for Targeted Protein Degradation |
| - | in-vitro, | BC, | NA |
| 6485- | Nimb, | Limonoids from neem (Azadirachta indica A. Juss.) are potential anticancer drug candidates |
| 6486- | Nimb, | Nimbolide: promising agent for prevention and treatment of chronic diseases |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 6487- | Nimb, | Anticancer properties of nimbolide and pharmacokinetic considerations to accelerate its development |
| - | Review, | Var, | NA |
| 946- | Nimb, | Nimbolide retards T cell lymphoma progression by altering apoptosis, glucose metabolism, pH regulation, and ROS homeostasis |
| - | in-vivo, | NA, | NA |
| 4973- | Nimb, | Nimbolide Exhibits Potent Anticancer Activity Through ROS-Mediated ER Stress and DNA Damage in Human Non-small Cell Lung Cancer Cells |
| - | in-vitro, | NSCLC, | A549 |
| 4970- | Nimb, | Insights into Nimbolide molecular crosstalk and its anticancer properties |
| - | Review, | Var, | NA |
| 4971- | Nimb, | Nimbolide, a Neem Limonoid, Is a Promising Candidate for the Anticancer Drug Arsenal |
| - | Review, | Var, | NA |
| 4972- | Nimb, | Chemopreventive and therapeutic effects of nimbolide in cancer: The underlying mechanisms |
| - | Review, | Var, | NA |
| 4974- | Nimb, | Nimbolide Induces ROS-Regulated Apoptosis and Inhibits Cell Migration in Osteosarcoma |
| - | in-vitro, | OS, | NA |
| 4975- | Nimb, | Nimbolide Induces Cell Apoptosis via Mediating ER Stress-Regulated Apoptotic Signaling in Human Oral Squamous Cell Carcinoma |
| - | in-vitro, | Oral, | NA |
| 4976- | Nimb, | Nimbolide inhibits pancreatic cancer growth and metastasis through ROS-mediated apoptosis and inhibition of epithelial-to-mesenchymal transition |
| - | vitro+vivo, | PC, | NA |
| 4977- | Nimb, | Nimbolide Inhibits SOD2 to Control Pancreatic Ductal Adenocarcinoma Growth and Metastasis |
| - | vitro+vivo, | PC, | AsPC-1 | - | in-vitro, | PC, | PANC1 |
| 7708- | NIV, | lpi, | Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial |
| - | Trial, | CRC, | NA |
| 7707- | NIV, | lpi, | Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial |
| - | Trial, | RCC, | NA |
| 6413- | NoProd, | The DRP1 receptor FIS1 is critical to the expansion of triple-negative breast cancer tumor-initiating cells |
| - | vitro+vivo, | BC, | MDA-MB-231 | - | in-vitro, | BC, | HS587T |
| - | Study, | AD, | NA |
| 6415- | NoProd, | Impaired Balance of Mitochondrial Fission and Fusion in Alzheimer's Disease |
| - | in-vivo, | AD, | NA |
| 1911- | Nos, | Noscapine inhibits tumor growth in TMZ-resistant gliomas |
| - | in-vitro, | GBM, | NA | - | in-vivo, | GBM, | NA |
| 150- | NRF, | CUR, | docx, | Subverting ER-Stress towards Apoptosis by Nelfinavir and Curcumin Coexposure Augments Docetaxel Efficacy in Castration Resistant Prostate Cancer Cells |
| - | in-vitro, | Pca, | C4-2B |
| 968- | OA, | Oroxylin A inhibits glycolysis-dependent proliferation of human breast cancer via promoting SIRT3-mediated SOD2 transcription and HIF1α destabilization |
| - | vitro+vivo, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MBT-2 |
| 991- | OA, | Blockade of glycolysis-dependent contraction by oroxylin a via inhibition of lactate dehydrogenase-a in hepatic stellate cells |
| - | in-vivo, | NA, | NA | - | in-vivo, | Nor, | NA |
| 1130- | OA, | Oroxylin A Suppresses the Cell Proliferation, Migration, and EMT via NF-κB Signaling Pathway in Human Breast Cancer Cells |
| - | in-vitro, | BC, | MDA-MB-231 |
| 1229- | OA, | Review of the Clinical Effect of Orlistat |
| - | Review, | NA, | NA |
| 7534- | OLE, | An oleuropein-based dietary supplement may improve joint functional capacity in older people with high knee joint pain: findings from a multicentre-RCT and post hoc analysis |
| - | Trial, | Arthritis, | NA |
| 7533- | OLE, | HT, | Systemic Health Effects of Oleuropein and Hydroxytyrosol Supplementation: A Systematic Review of Randomized Controlled Trials |
| - | Review, | Nor, | NA |
| 4630- | OLE, | Targeting resistant breast cancer stem cells in a three-dimensional culture model with oleuropein encapsulated in methacrylated alginate microparticles |
| - | in-vitro, | BC, | NA |
| 4629- | OLE, | Oleuropein exhibits anticancer effects by inducing apoptosis and inhibiting cell motility in MCF7 and MDA-MB231 breast cancer cells |
| - | in-vitro, | BC, | MDA-MB-231 | - | NA, | NA, | MCF7 |
| 4643- | OLE, | HT, | Use of Oleuropein and Hydroxytyrosol for Cancer Prevention and Treatment: Considerations about How Bioavailability and Metabolism Impact Their Adoption in Clinical Routine |
| - | Review, | Var, | NA |
| 4628- | OLE, | Effects of oleuropein on tumor cell growth and bone remodelling: Potential clinical implications for the prevention and treatment of malignant bone diseases |
| - | in-vitro, | Var, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:% State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid